Sessile serrated adenoma (SSA), also referred to as sessile serrated polyp (SSP), has been proposed as a precursor lesion to microsatellite unstable carcinoma. However, the mechanism of stepwise progression from SSA to early invasive carcinoma has been unclear. The purpose of this study was to elucidate the histological characteristics and possible role of p53, β-catenin, BRAF, KRAS, and PIK3CA in the development and progression of SSA. We analyzed 12 cases of SSA with neoplastic progression (SSAN), (6/12) and 41.7% (5/12) of SSANs, respectively, and were exclusively present in HGD/carcinoma areas. By contrast, neither nuclear β-catenin nor p53 expressions were seen in HPs or SSAs (p < 0.0001). BRAF mutations (V600E) were observed in 45.8% (11/24) of HPs, 60.9% (14/23) of SSAs, and 63.6% (7/11) of SSANs, and were equally found in both SSA and carcinoma/HGD areas of the individual SSANs. KRAS exon1 mutations were uncommon in all 3 groups (4.2%, 4.4%, and 0%, respectively). No mutations of PIK3CA exon9 or exon20 were found in any cases examined. These findings suggest that BRAF mutations may be associated with the pathogenesis of SSA, but progression to HGD or early invasive carcinoma may be associated with other K Fujita et al. 4 / 27 factors such as alterations of p53 and β-catenin. In addition, our histological observations suggest a possible close association between SSAN and mucinous adenocarcinoma.
Introduction
Most colorectal cancers develop through a conventional adenoma-carcinoma sequence characterized by chromosomal instability and stepwise accumulation of multiple genetic mutations such as APC/β-catenin, KRAS, and p53. 38 Recent increasing evidence suggests that 10% to 20% of colorectal cancers develop via another pathway, known as the "serrated polyp-neoplasia pathway." Such carcinomas may originate from serrated polyps. The endpoint carcinomas of this pathway are assumed to be associated with BRAF mutation, DNA hypermethylation, and microsatellite instability (MSI). 16, 25, 40 Serrated polyps are histologically classified into hyperplastic polyp (HP), traditional serrated adenoma (TSA), sessile serrated adenoma (SSA), and mixed hyperplastic/adenomatous polyp. 34 In particular, there are many clinicopathological and genetic similarities between SSA and MSI-high colorectal cancers; e.g., right-sided predilection, decreased expression of DNA mismatch repair protein hMLH1, frequent BRAF mutation, and infrequent KRAS mutation. 7, 10, 28, 36 Therefore, SSA can be considered as the precursor to some populations of MSI-high carcinomas of the proximal colon. 34 Thus, there is a growing consensus that SSA has a significant risk of malignant change and that SSA should be carefully treated despite a lack of overt cytological atypia. However, the details of the molecular mechanism of stepwise progression of SSA remain unclear. In fact, carcinomas actually arising from SSAs are rarely encountered in routine pathological practice. Therefore, investigation of SSA with early neoplastic progression may give insights into the understanding and prevention of the progression of the serrated neoplasia pathway, a clinically important subject.
In colorectal cancer, KRAS, BRAF, and PIK3CA mutations have been considered to play an important role in tumorigenesis by activating the RAS-RAF-MAPK or K Fujita et al. 6 / 27 PI3K-PIP3-AKT signaling pathways. 6, 21, 31 Recently, mutations in the PIK3CA gene, which encodes the p110α catalytic subunit of phosphatidylinositol 3-kinases (PI3Ks), have been found in 10% to 30% of colorectal cancer cases. Because oncogenic RAS also activates PI3Ks, the PI3K signaling pathway via RAS mutation or PIK3CA mutation is considered to play an important role in colorectal carcinogenesis. 3, 21 In fact, the presence of PIK3CA mutation is reported to be associated with KRAS mutation, MSI, and worse prognosis of colon carcinomas. 1, 3, 26, 31 However, the prevalence and clinicopathological significance of PIK3CA mutation in serrated pathway-derived carcinomas are unclear.
The aims of this study were to elucidate the clinicopathological and morphologic features of SSA with histological progression and investigate the potential roles of p53, β-catenin, BRAF, KRAS, and PIK3CA mutations. Membranous labeling without nuclear expression was considered normal. Nuclear β-catenin accumulation (moderate to strong expression in > 5% of the epithelium) and loss of membranous β-catenin expression were considered to be abnormal reactivities.
Materials and Methods

Cases and histological evaluation
p53 staining was interpreted as either positive (moderate to strong expression in > 50% of the epithelium) or negative (negative, weak staining, or moderate or strong expression in < 50% of the epithelium).
Detection of mutations of BRAF, KRAS, and PIK3CA genes
Genomic DNA was extracted from formalin-fixed, paraffin-embedded 5'GCTAGAGACAATGAATTAAGGGAAA3' (PIK3CA-exon9-forward);
5'AGCACTTACCTGTGACTCCA3' (PIK3CA-exon9-reverse);
5'AACTGAGCAAGAGGCTTTGG3' (PIK3CA-exon20-forward);
5'CTTTTCAGTTCAATGCATGCTG3' (PIK3CA-exon20-reverse). The amplified PCR products were then purified using Montage centrifugal filters (Millipore, Bedford, MA, USA). After purification, direct sequencing was carried out using a Perkin Elmer ABI PRISM 310 sequence analyzer (Applied Biosystems, Foster City, CA, USA). If the quality of DNA or level of PCR amplification was insufficient for mutation analysis, the cases were excluded from the molecular study.
Statistical Analysis
We performed the χ 
Results
Clinicopathological findings
The comparison of clinicopathological findings among 66 HPs, 53 SSAs, and 12 SSANs are summarized in Table 1 . The detailed clinicopathological findings of 12
SSANs are also listed in SSANs and SSAs were preferentially located in the right colon compared with HPs (p < 0.0001).
Histological findings
Microvesicular type HPs showed crypts that were predominantly serrated on the surface, but predominantly tapered and narrow at the deeper mucosa (Fig. 1A) . Most crypt epithelium contained abundant microvesicular mucin, and goblet cells were less frequent.
SSAs showed crypts that were irregularly dilated or serrated from the surface to the deeper mucosa, and horizontal branching or budding at the crypt bases (Fig. 1B) .
Focal nuclear enlargement and pseudostratification were also noted.
Among 12 cases of SSANs, 7 (58.3%) contained areas of high-grade dysplasia (HGD) and 5 (41.7%) contained areas of adenocarcinoma invading the submucosa (Table 2 ). The histological features of the HGD area ( no. 12). Blood vessel invasion of carcinoma cells was not present in any case of SSAN.
In addition, lymph node metastasis was found in one case of adenocarcinoma (Case no.
10).
Immunohistochemical findings
The results of immunohistochemical staining are summarized in Tables 3 and 5 .
Aberrant p53 nuclear accumulation was observed in 41.7% (5/12) of SSANs. All cases of HP and SSA were negative for p53 nuclear expression (Fig. 2) . The incidence of aberrant p53 expression was higher in SSAN than in HP and SSA (each p < 0.0001).
Nuclear β-catenin accumulation was observed in 50% (6/12) of SSANs, but not at all in HPs or SSAs (each p < 0.0001) ( 
Mutation analysis
The results of mutation analysis of exon 15 of BRAF, exon 1 of KRAS, and exons 9 and 20 of PIK3CA are summarized in Table 4 . The V600E (T to A transversion) BRAF mutations were observed in 45.8% (11/24) of HPs, 60.9% (14/23) of SSAs, and 63.6% (7/11) of SSANs (Fig. 4) . As for SSAN, both SSA and HGD/carcinoma K Fujita et al. 14 / 27 components showed essentially the same mutation pattern (see below). There was no significant difference in the prevalence of BRAF mutation among the 3 groups. In all 3 groups, the presence of BRAF mutation did not correlate with clinicopathological features, such as anatomic location, polyp size, and gender.
KRAS mutations were uncommon in all 3 groups; only each single case of HP and SSA had KRAS mutations in codon 12 (G12S) and codon 13 (G13D), respectively.
BRAF mutations and KRAS mutations were mutually exclusive; the case with BRAF mutation had no KRAS mutation, and vice versa. No PIK3CA mutations were found in any case of HP, SSA, or SSAN.
Comparison between adjacent SSA area and HGD/carcinoma area in SSAN
The results of immunohistochemical staining and molecular analysis using microdissection methods in SSAN is summarized in Table 5 . In all but one patient, both SSA and HGD/carcinoma components had the same V600E mutations. HGD/carcinoma components showed frequent nuclear p53 and β-catenin nuclear accumulation, whereas the adjacent SSA areas showed no nuclear accumulation of these proteins. There was no significant correlation between the presence of BRAF mutation and β-catenin expression or p53 nuclear expression in HGD/carcinoma components of SSAN.
Comparison between morphological growth patterns of the HGD/carcinoma area in SSAN (tubular/tubulovillous type vs. serrated type)
As for the HGD/intramucosal carcinoma component of 12 cases of SSAN, there was no significant difference of the prevalence of BRAF mutation, β-catenin expression, or p53 nuclear expression between the tubular/tubulovillous type (n = 9) and previous reports by Goldstein et al. 9 Additionally, we found that tubular adenomatous high-grade dysplastic areas and SSAs shared the same BRAF mutation pattern. This is contrary to the fact that sporadic conventional tubular adenoma hardly harbored BRAF mutation. 18, 35 These findings support the fact that SSAN in this study was not a collision but a stepwise transitional lesion. Iino et al. also reported similar molecular changes in both HPs and tubular adenomatous components in the study of MSI status of K Fujita et al. 17 / 27 12 cases of "mixed polyps." 13 It is also noteworthy that 83% (10/12) of SSANs were located in the proximal colon, and 58% (7/12) of SSANs, including all 5 cases of invasive carcinoma, showed increased extracellular mucin production. Sheridan et al. had also noticed extracellular mucin and "signet-type" mucinous carcinoma in their series of SSAN; however, the description was only in the figure legends, and the details of prevalence and clinicopathological associations had not been documented. 33 Lu et al. recently described that subsequent colon carcinomas in patients with prior SSA diagnosed by biopsy exhibited the features of mucinous or medullary carcinoma; these phenotypes are usually associated with MSI. 19 In our series, we specifically demonstrated the close association or overlap between SSAN and mucinous "colloid-type" adenocarcinoma. In fact, right-sided mucinous carcinoma is also associated with the MSI-H phenotype and expression of MUC5AC mucin core proteins, as in SSA. 2, 8, 12, 30 In the current study, most HPs and SSAs had BRAF mutation, whereas KRAS mutation was rarely present in such serrated polyps. This result is consistent with several previous reports showing that BRAF, rather than KRAS, mutation is the predominant genotype in SSAs. 14, 25, 40 Likewise, both benign and high-grade components of SSA-derived dysplasia/carcinoma harbored frequent BRAF mutation but no KRAS mutation in our series. This result suggests that BRAF, rather than KRAS, mutation may play an important role in the early steps of SSA formation, and both genes may have no major role in the malignant progression of SSA.
In this investigation, we found that aberrant nuclear p53 expression was present in 43% (3/7) of high-grade dysplastic areas and 40% (2/5) of invasive carcinoma areas of SSANs, but not in nondysplastic areas of SSANs, HPs, or SSAs. Parfitt et al. also K Fujita et al. 18 / 27 reported a greater degree of p53 expression in high-grade dysplastic areas than in nondysplastic or low-grade dysplastic areas in a study of 11 cases of SSA with dysplasia. 29 This phenomenon is similar to that seen in the conventional tubular adenoma-carcinoma sequence. As we did not examine p53 gene mutation in this study, the interpretation of p53 protein immunostaining might be debatable concerning the discrimination between wild-and mutant-type protein expression. However, it has been reported that nuclear p53 expression in more than 50% of tumor cells is closely associated with the presence of p53 mutation in the malignant component of the tubular adenoma-carcinoma sequence. 5 In our SSAN series, the vast majority of high-grade cells showed p53 immunoreactivity when a nuclear accumulation of p53 was present.
Therefore, the inactivation of p53 due to its gene mutation might play an important role in the malignant progression of SSA.
The presence of BRAF mutation in benign serrated polyps (HP and SSA) and the subsequent occurrence of p53 nuclear accumulation in association with malignant progression lead us to hypothesize that this phenomenon may be similar to the oncogene-induced senescence and escape from senescence checkpoint seen in the transition from cutaneous nevus to malignant melanoma. This idea is essentially consistent with the proposal by Minoo and Jass. whether the concept of oncogene-induced senescence and evasion from it can be exactly applied to the serrated neoplasia pathway because we have not examined the expression of senescence-associated β-galactosidase in serrated polyps and related carcinomas.
However, the introduction of such a novel oncogenic concept might help to establish diagnostic and therapeutic strategies in the serrated neoplasia pathway.
Some investigators have reported that abnormal nuclear β-catenin expression was observed in 42.8% to 100% of SSAs with low-grade dysplasia. 15, 39 In the current series, aberrant nuclear accumulation of β-catenin was also observed in half of SSANs,
and it was present exclusively in the high-grade dysplastic component but not in non-dysplastic SSA. Cumulative data and our results suggest that nuclear accumulation of β-catenin may be closely related to early progression of SSA. β-catenin is one of the target genes of the Wnt pathway, and gene alteration of β-catenin itself and its regulators, such as APC, is well studied in conventional tubular adenoma and related carcinomas.
We cannot yet draw a conclusion about the molecular basis of nuclear accumulation of β-catenin in SSAN. However, the presence of nuclear β-catenin accumulation might evoke the possibility of a common mechanism between the adenoma-carcinoma sequence and serrated neoplasia pathway, proposed as the "fusion pathway" by Jass et al. 14 To the best of our knowledge, this study was the first to investigate the prevalence of PIK3CA mutations in SSA and related high-grade dysplasia and carcinomas. As a result, no PIK3CA mutations were detected in any case of benign or malignant serrated lesions. This result suggests that the PIK3CA mutation is a quite rare event in the early phase of the serrated neoplasia pathway, although there remains a possibility that this gene mutation may emerge in the latter stages of carcinogenesis, similar to the (G). Low-power view of invasive adenocarcinoma arising in SSA (same case as Figure   1F ). Extracellular mucin production is prominent in the invasive front.
(H). High-power view of an invasive adenocarcinoma area (same case as Figure 1F ). GTG-to-GAG change (V600E) at codon 600.
